d-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions
Introduction
One particular success of translational research is the investigation of d-cycloserine (DCS), a partial agonist of the glycine recognition site of the N-Methyl-d-Aspartate receptor (NMDAr), as an augmentation strategy for exposure-based cognitive behavioral therapy for the anxiety disorders (Davis et al., 2006, Hofmann et al., 2011). Following a series of studies indicating that extinction learning is NMDAr dependent (see Davis et al., 2006), Davis and colleagues first demonstrated that DCS can enhance retention of fear extinction in rats and subsequently showed that DCS enhances the outcome of extinction-based therapy (i.e., virtual reality exposure therapy) for height phobia (Davis et al., 2006). These initial findings created great excitement among anxiety disorder treatment researchers who have been faced with the challenge to improve the outcomes of exposure-based CBT for anxiety disorders such as social anxiety disorder (Hofmann and Smits, 2008), which are prevalent and associated with significant personal and economic costs (Greenberg et al., 1999, Kessler et al., 2005). Not surprisingly, the last several years have seen a number of studies evaluating the efficacy of DCS for enhancing outcomes for exposure-based CBT (Hofmann et al., 2011).
The efficacy of d-cycloserine (DCS) for enhancing exposure therapy has been variable across these studies, with several evidencing strong augmentative effects of DCS (Guastella et al., 2008, Hofmann et al., 2006, Otto et al., 2010, Ressler et al., 2004), and several showing either relatively weak effects (Kushner et al., 2007, Wilhelm et al., 2008), no effects (Guastella et al., 2007, Storch et al., 2007, Tart et al., 2013), or even detrimental effects (Litz et al., 2012). Animal research has pointed to the adequacy of extinction training, as indexed by sufficient decrement in fear responding during the training session, as a potential moderator of the augmentation effects of DCS. Indeed, in re-analyses of null findings, Weber and colleagues (Weber et al., 2007) and Bouton and colleagues (Bouton et al., 2008) demonstrated that the efficacy of DCS for facilitating extinction retention was evident only in animals that had demonstrated a large decrement in fear responding during extinction training.
Analogous to these animal studies, we recently reanalyzed a null finding for DCS augmentation from a small-scale trial involving patients (N = 29) undergoing exposure therapy for height phobia. The original analyses revealed that patients receiving 50 mg of DCS administered following each of two sessions of 30 min of hierarchical virtual reality exposure did not evidence better clinical outcomes than patients receiving identical exposure combined with placebo (Tart et al., 2013). In our reanalysis of these findings (Smits et al., 2013b), we tested whether the effects of DCS administration on subsequent clinical improvement would be moderated by the relative success of the exposure session. Because the exposure session was delivered in a hierarchical fashion (i.e., gradually moving up a simulated glass elevator), we indexed exposure success (or decrement in fear responding) using the fear level that patients reported at the end of the session, while controlling for baseline severity, the number of floors completed in the exposure hierarchy, and the level of fear reported at the beginning of the exposure session. Consistent with the findings from animal studies (Bouton et al., 2008, Weber et al., 2007), the result of this reanalysis showed that DCS facilitated clinical improvement when patients ended their previous exposure session with low fear levels, and, conversely, inhibited clinical improvement when patients ended their previous exposure session with elevated fear levels (Smits et al., 2013b). Assuming clinicians accurately targeted patients' fears with challenging exposure assignments, low end fear provides a measure of extinction success, consistent with preclinical studies (Lee et al., 2006). Replication and extension of this potential marker for the successful use of DCS has important implications for the clinical application of DCS augmentation strategies.
The present paper represents the first reanalysis of a large-scale trial of DCS augmentation. Specifically, in the largest clinical trial of DCS augmentation published to date, Hofmann et al. (Hofmann et al., 2013) found that DCS augmentation of exposure-based CBT for social anxiety disorder resulted in faster, but not greater, treatment response than placebo augmentation. Based on the extant research, we hypothesized that the relative advantage conferred by DCS administration on clinical improvement would be moderated by the success of the exposure session, such that advantage of DCS over placebo with respect to clinical improvement would be greater following sessions characterized by low end fear levels than following sessions characterized by elevated end fear levels. Building further upon our previous study (Smits et al., 2013b), we also explored in this paper the possibility that within-session extinction (i.e., peak fear minus end fear), an alternative operationalization of exposure success (Smits et al., 2013b), is a more critical dimension for moderating the efficacy of DCS than end fear.
Section snippets
Participants
Participants in the trial were 169 adults with a diagnosis of generalized SAD utilizing the Structured Clinical Interview for DSM-IV Diagnosis (First et al., 2001) and a score of 60 or higher on the Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987). Exclusion criteria included (a) medical disorders of clinical significance; (b) lifetime history of obsessive-compulsive disorder, bipolar disorder, schizophrenia, psychosis, or delusional disorders; (c) diagnosis within the past 6 months of
Data analysis
Data were analyzed using multilevel models (MLM), which is the recommended analytic approach for psychiatric data (Hamer and Simpson, 2009). To determine if End Fear moderated the effect of condition (DCS vs. Placebo) on CGI-I at the next session, our model included the following predictors: End Fear (as a level 1 time-varying predictor of CGI-I at the next session), Condition, and End Fear × Condition. Because End Fear was an observed variable, we included several variables to control for
Results
The sample of 145 participants was 41.8% female and 9.2% African American. Their mean age was 32.5 (SD = 10.5) and 77.9% were cohabitating with a partner. End Fear ratings ranged from 0 to 100 (M = 49.5; SD = 19.2), and Beginning Fear ranged from 10 to 100 (M = 66.7; SD = 17.8). Average End Fear across the 5 augmented sessions ranged from 5 to 83.8 (M = 49.2; SD = 15.5) and Average Beginning Fear across the 5 augmented sessions ranged from 30 to 100 (M = 66.7; SD = 14.5).
Discussion
The present study reported on a re-analysis of the largest clinical trial of DCS enhancement of exposure therapy to date (Hofmann et al., 2013). Guided by preclinical research (Bouton et al., 2008, Lee et al., 2006, Weber et al., 2007) and initial findings from a small-scale study involving humans (Smits et al., 2013b), we tested the hypothesis that DCS enhancement of fear extinction would be specific to successful exposure sessions. Consistent with predictions, we found that patients who
Role of funding source
This study was funded by NIH grants R01MH078308 and R01MH075889 from the National Institute of Mental Health. The sponsor (NIH) had no role in the design and conduct of the study, in the collection, management, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript. Drs. Smits, Pollack, and Hofmann had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Contributors
JAJS, DR, MWO, LM, MHP, SG designed the study, conducted the literature searches, participated in the data analyses, and wrote a first draft of the manuscript. MLD, AEM, NMS, and assisted with the design and implementation of the study, interpretation of the data and the writing of the manuscript. All authors contributed to and approved the final manuscript.
Conflict of interest
Dr. Smits receives royalties from various book publishers. Dr. Rosenfield, Ms. Davis. Dr. Marques and Dr. Simon report no financial relationships with commercial interests. Dr. Otto has served, in the last three years, as consultant for MicroTransponder, Inc. and receives royalties from various book publishers. Dr. Meuret reported serving as a consultant for Palo Alto Health Sciences Inc. Dr. Pollack's disclosures over the last three years include: Advisory Boards and Consultation: Eli Lilly,
References (41)
- et al.
d-cycloserine facilitates context-specific fear extinction learning
Neurobiology of Learning and Memory
(2008) - et al.
Optimizing inhibitory learning during exposure therapy
Behaviour Research and Therapy
(2008) - et al.
Effects of d-cycloserine on extinction: translation from preclinical to clinical work
Biological Psychiatry
(2006) - et al.
A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear
Journal of Psychiatric Research
(2007) - et al.
A randomized controlled trial of the effect of d-cycloserine on enhancement of exposure therapy for social anxiety disorder
Biological Psychiatry
(2008) - et al.
The pattern of subjective anxiety during in-session exposures over the course of cognitive-behavior therapy for clients with social anxiety disorder
Behaviour Therapy
(2008 Sep) - et al.
Cognitive enhancers for anxiety disorders
Pharmacology Biochemestry and Behavior
(2011) - et al.
d-cycloserine augmented exposure therapy for obsessive-compulsive disorder
Biological Psychiatry
(2007) - et al.
A randomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorder
Journal of Psychiatric Research
(2012) - et al.
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder
Biological Psychiatry
(2010)
The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: a controlled investigation
Behaviour Research and Therapy
d-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia
Biological Psychiatry
Augmentation of exposure therapy with post-session administration of d-cycloserine
Journal of Psychiatric Research
Effects of d-cycloserine on extinction of learned fear to an olfactory cue
Neurobiology of Learning and Memory
Multiple regression: testing and interpreting interactions
Extinction retention predicts improvement in social anxiety symptoms following exposure therapy
Depression and Anxiety
Case matching and the reduction of selection bias in quasi-experiments: the relative importance of pretest measures of outcome, of unreliable measurement, and of mode of data analysis
Psychological Methods
Structured clinical interview for DSM-IV axis-i disorders, clinician version
Cognitive reappraisal self-efficacy mediates the effects of individual cognitive-behavioral therapy for social anxiety disorder
Journal of Consulting and Clinical Psychology
The economic burden of anxiety disorders in the 1990s
Jounal of Clinical Psychiatry
Cited by (102)
Cognitive-Behavioral Therapy Enhancement Strategies
2024, Psychiatric Clinics of North AmericaUsing pre-treatment de novo threat conditioning outcomes to predict treatment response to DCS augmentation of exposure-based CBT
2023, Journal of Psychiatric ResearchDoes fear reduction predict treatment response to exposure for social anxiety disorder?
2023, Journal of Behavior Therapy and Experimental PsychiatryUse of experimental medicine approaches for the development of novel psychiatric treatments based on orexin receptor modulation
2023, Neuroscience and Biobehavioral ReviewsHormonal, reproductive, and behavioural predictors of fear extinction recall in female rats
2020, Hormones and BehaviorCitation Excerpt :A number of clinical studies have also demonstrated no relationship between fear levels at the end of an exposure therapy session and overall treatment outcomes (see Craske et al., 2008). For instance, Smits et al. (2013) found that treatment outcomes for placebo-treated patients receiving exposure therapy for Social Anxiety Disorder did not depend upon levels of self-reported fear exhibited at the end of each exposure session. However, a relationship between treatment outcomes and self-reported fear at the end of each exposure session did emerge for DCS-treated patients.